Yield10 Bioscience (YTEN) Issues Update on Omega-3 Camelina Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- SpaceX stock drops amid spaceport lawsuit, debt concerns
Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program
February 7, 2024 5:40 PM EST-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024
-Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile
- Company also Provides Update on Nasdaq Status -
WOBURN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (Yield10 or the Company), an agricultural bioscience company, today provided an update on its Omega-3 Camelina program. The Company has taken the strategic decision to prioritize in 2024 the execution of activities intended to accelerate and advance the Omega-3 Camelina program toward... More



